Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced on Nov. 4, 2025 that it granted a total of 26,550 restricted stock units (RSUs) to two newly hired employees as inducements under its 2024 Inducement Stock Incentive Plan.
The RSUs vest in four equal annual installments on each one‑year anniversary of the grant date through the fourth anniversary, and vesting is subject to each employee's continued service. The grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction 50 Alerts
On the day this news was published, SLDB declined 15.29%, reflecting a significant negative market reaction. Argus tracked a peak move of +12.5% during that session. Argus tracked a trough of -17.5% from its starting point during tracking. Our momentum scanner triggered 50 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $73M from the company's valuation, bringing the market cap to $405M at that time. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 26,550 restricted stock units (“RSUs”) to two newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
What did Solid Biosciences (SLDB) announce on Nov. 4, 2025 about RSU inducement grants?
How do the RSUs granted by SLDB vest and what is the timeline?
Are the SLDB RSU awards conditional on continued employment?
Under which plan and Nasdaq rule were the SLDB inducement grants made?
How many employees received RSU inducement grants from SLDB on Nov. 4, 2025?
